Global Acute Coronary Syndrome Treatment Market Report and Forecast 2024-2032

Global Acute Coronary Syndrome Treatment Market Report

The acute coronary syndrome treatment market attained a value of USD 9.60 billion in 2023, driven by the rising prevalence of coronary heart disease. The market is likely to increase at a CAGR of 6.05% during the forecast period of 2024-2032 to attain a value of USD 16.30 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Company News

In July 2023, the combination of highly sensitive troponin testing and combined negative copeptin helped in the early discharge from the ICUs in the United States.  This will be helpful in ruling out the risk of the acute coronary syndrome in patients.

In June 2023, a new diagnostic technique, the synthetic intelligence (AI) approach, was developed to detect plaque erosions in coronary arteries and thus help in the early treatment of the acute coronary syndrome. 

Acute Coronary Syndrome: Disease Insights, Symptoms, and Pathophysiology

Acute coronary syndrome is a cardiac disease leading to the partial or complete blockage of blood flow to the heart. This syndrome consists of three subtypes: Unstable Angina, Non-ST-Elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). With time, patients with unstable angina have also been covered under Non-ST-Elevation myocardial infarction due to the increased use of the High Sensitivity Troponin Test. 

People with obesity and unhealthy lifestyles are at a higher risk of suffering from acute coronary syndrome. The primary cause of this syndrome is the formation of a blood clots, which is caused due to the rupturing of the plaques (fatty deposits) in and on the walls of coronary arteries and blood vessels. 

These blood clots lead to the blockage of blood flow to the heart muscles and thus lead to temporary blockage or even cell death. Other causes of this syndrome are Spontaneous Coronary Artery Dissection and Coronary Artery Spasm.

Acute Coronary Syndrome Diagnosis 

The signs and symptoms of the acute coronary syndrome include chest pain, dizziness, sudden sweating, fatigue, heart palpitations, and shortness of breath. Physical exams, blood tests, and Electrocardiograms (EKGs) are the primary tests for diagnosing acute coronary syndrome and help record the heart’s electrical activity.

Electrocardiogram tests measure the heart's electrical activity, which helps identify the blockage. Blood tests help determine the concentration of certain enzymes, indicating the heart tissue's status.

Additional imaging tests like Computed Tomography (CT) scans or Heart Magnetic Resonance Imaging (MRI) are also used to produce detailed pictures of the heart. The Cardiac Perfusion Test is also used to determine whether the heart is getting sufficient blood.

Acute coronary syndromes can be treated by a group of medications and surgical procedures to open the blockages. Acute coronary syndrome is more prevalent in men than women due to the different lifestyle patterns.

The increasing inclination of today’s youth toward a sedentary lifestyle increases the risk of acute coronary syndrome. Hence, this can be a promising driving factor in the acute coronary syndrome treatment market growth.

According to the acute coronary syndrome market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Indication

• Vial Unstable Angina 

• ST-Elevation Myocardial Infarction 

• Non-ST-Elevation Myocardial Infarction

• Others

Market Breakup by Class

• Anti-Hypertensive

• Antithrombotic 

• Statins 

• Others

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America

• United States of America

• Canada

• Europe

• United Kingdom

• Germany

• France

• Italy

• Others

• Asia Pacific

• China

• Japan

• India

• ASEAN

• Australia

• Others

• Latin America

• Brazil

• Argentina

• Mexico

• Others

• Middle East and Africa

• Saudi Arabia

• United Arab Emirates

• Nigeria

• South Africa

• Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Acute Coronary Syndrome Treatment Market Trends

The value of the acute coronary syndrome treatment market is driven by the rising prevalence of cardiovascular diseases. The number of cardiovascular disorders diagnosed cases was nearly 547 million in 2021. The prevalence of the disease is likely to grow at a rate of 2.3% in the forecast period of 2024-2032. With this growth rate, the number of cases is expected to reach approximately 671 million by 2030.

Increasing Prevalence of Cardiovascular Disorders

According to World Health Organization, the global prevalence of acute coronary syndrome was 523 million in 2019, with 17.9 million deaths worldwide . Acute coronary syndrome is most prevalent in the Asia Pacific regions, accounting for more than 50% of the world’s total cases.

This increasing prevalence of cardiovascular disorders and sudden cardiac arrest is responsible for driving the growth of the acute coronary syndrome treatment market. This is stimulating the demand for novel therapeutic options and hence will facilitate market growth. 

The clinical algorithms for managing acute coronary syndrome in Australia and New Zealand are generally comparable with Europe and the United States of America. In contrast, the algorithms among the other parts of Asia show mutability according to the situation. Thus, developed nations account for the major burden of the global acute coronary syndrome treatment market.

Rising Geriatric Population

The acute coronary syndrome (ACS) is more common among the geriatric population. Globally, the highest incidence of acute coronary syndrome have been recorded in Latin American and the Middle Eastern regions.

According to the survey results, the prevalence of acute coronary syndrome will rise in developing countries (China, Sub-Sahara Africa, India, Latin America, and the Far East). The prevalence of ACS is rising in developing countries due to the increased sedentary lifestyle, smoking, and obesity. 

Most European countries have significantly decreased the age-standardised death rates for ACS in the last decades. This is due to the improvement of cardiovascular prevention and treatment. Through the studies, it is projected that ACS is more prevalent in blacks than whites. The increased cases of cardiovascular disorders are also boosting the global acute coronary syndrome treatment market growth.

Novel Product Launches and Approvals

Novel product launches and approvals are also expected to facilitate the expansion of the acute coronary syndrome treatment market. This is contributing to the increased collaborations among the key players and companies. The collaborations will substantially boost the revenue of the acute coronary syndrome treatment market.

Among the types of ACS, non-ST segment elevation has nearly remained constant, while the ST segment elevation has decreased significantly in the last few years. Despite modern advancements in medical and interventional therapies, there is still a substantial increase in new cases and mortalities among people all over the globe.

Therapeutic Landscape

Acute coronary syndrome is a syndrome caused by the decreased blood flow in the coronary arteries leading to the malfunctioning or death of the heart tissue. This is mainly caused due to the atheroma rupture leading to the blockage of the arteries.

The primary idea behind eradicating acute coronary syndrome is to minimise the symptoms in the short and long run. The treatment is based on three mechanisms- Relieve pain and distress, improve blood flow, and restore heart function in the best way possible.

Therapeutic Agents contributing to the Share of the Acute Coronary Syndrome Treatment Market

Depending on the diagnosis, the following types of medications are being prescribed by the health physicians:

• Thrombolytics or Anti Coagulating agents play a significant role in dissolving the blood clot, hindering the blood flow pathway.

• Nitroglycerins help improve blood flow by broadening the blood vessels.

• Antiplatelet drugs prevent the development of blood clots and act as blood thinning agents.

• Beta-blockers act by relaxing the heart muscles and thus leading to less pressure on the heart and lower blood pressure.

• Angiotensin-Converting Enzyme (ACE) inhibitors increase the heart’s productivity by broadening the blood vessels and thereby increasing the blood flow.

• Angiotensin Receptor Blockers help in controlling blood pressure.

• Statins majorly help in cholesterol control. They lower cholesterol levels and stabilise plaque deposits.

If the condition is extreme or the medications fail to work, then there is the need for surgical procedures to restore the blood flow to the heart muscles. The following surgeries may be prescribed:

• Angioplasty and Stenting: This is mainly based on the insertion of a catheter into the blocked artery. The catheter passes a thin wire carrying deflated balloon to the blocked artery, which gets engorged inside, causing the compression of the plaque layers against the arterial walls. A stent can also be inserted to open the artery, leading to normal blood flow.

• Coronary Bypass Surgery: In this procedure, the surgeon takes a graft from one part of the body and creates a novel route for blood flow through the blocked artery.

• Percutaneous Coronary Intervention: This procedure is applied to open a blocked artery.

From an international perspective, the cumulative direct and indirect costs of patients with acute coronary syndrome are estimated to be USD 1.26 million. The average cost per acute coronary syndrome patient in the United States` is USD 10.4 billion annually. 

The initial prices are less for medical treatment than for percutaneous coronary intervention and coronary artery bypass graft. But several interventions are required for the chronic term, thus, accounting for increased costs and giving a brighter global acute coronary syndrome treatment market outlook.

With the high treatment potential, there is an excellent opportunity for healthcare industries and pharmaceutical companies in drug development and novel diagnostics methods.

Clinical Trials for Emerging Therapeutic Interventions

Several clinical trials for ACS are being developed and researched by healthcare organisations and pharma companies. To get a safer and more efficient treatment for acute coronary syndrome, investigators continuously search, analyse, and reformulate current therapies and treatments. They are more drawn toward the study of the new treatment with new targeted therapies.

Clinical trials for Polyprenols were completed in 2018 and seemed to be an effective treatment for acute coronary syndrome at the Russian Institute of Medical Sciences. Apixaban, a drug by Bristol-Myers Squibb, has also undergone Phase 3 clinical trials and can soon be an effective medication for ACS.

Several individual pharmacological agents, such as antiplatelet drugs, β-blockers, ACE inhibitors, and lipid-lowering agents, have also been tested. These combinations have efficiently reduced mortality in patients with acute coronary syndromes.

The antiplatelet agent clopidogrel has also been proven beneficial in treating non-ST-segment elevation acute coronary syndrome patients. Rivaroxaban, a drug funded by Johnson & Johnson Pharmaceutical Research & Development, also reduced the risk of the composite end point of death from the acute coronary syndrome, other cardiovascular causes, myocardial infarction, and stroke. Ticagrelor monotherapy has also been proven to prevent net combined ischemic and bleeding events.

Acute Coronary Syndrome: Drugs in Pipeline

Clinical researchers have also discovered many novel targeted therapies for better management of acute coronary syndrome. In Phase II, clinical trials have also demonstrated promising results from anti-inflammatory agents like tocilizumab and ZD5718.

In early phase trials, antithrombotic agents like Revacept, PZ-128, Vicagrel and Selatogrel have shown excellent results, and some are still in the exploration phase. The tests concluded that Dual Anti-Platelet Therapy would remain the cornerstone strategy for treating acute coronary syndrome. Still, these newly discovered agents can be included as adjunctive agents for the chronic treatment of acute coronary syndrome.

Brilanta, an anti-platelet drug developed by AstraZeneca, treats acute coronary syndrome by decreasing platelet aggregation and preventing blood clots. The Food and Drug Administration also approved the generic version of Plavix to reduce heart attacks or stroke risks in patients with atherosclerosis.

AUGUSTUS trials done by Pfizer in collaboration with Bristol-Myers Squibb gave positive results in Phase 4; soon, this can also be used to treat acute coronary syndrome. Several ongoing clinical trials are emerging as a driving factor for acute coronary syndrome treatment market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the acute coronary syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Pfizer Inc.

• Sanofi S.A.

• GSK plc

• Merck & Co., Inc.

• Amgen Inc.

• Arena Pharmaceuticals

• AstraZeneca plc

• Baxter International Inc.

• Bayer AG

• Biogen Inc.

• C. H. Boehringer Sohn Co. KG

• Eli Lilly and Company

• Gilead Sciences, Inc.

• Teva Pharmaceutical Industries Ltd.

Key Highlights of the Report